Last reviewed · How we verify
MRXXX
At a glance
| Generic name | MRXXX |
|---|---|
| Also known as | Experimental capsule formulation compared to marketed reference product |
| Sponsor | Mundipharma Research Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Whether 3 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication (PHASE1)
- A Study of Whether 2 New Oral Formulations of a Strong Pain Killer Release the Same Amount of Drug Into the Body as the Marketed Medication (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MRXXX CI brief — competitive landscape report
- MRXXX updates RSS · CI watch RSS
- Mundipharma Research Limited portfolio CI